Pharmacologic management of neuropsychiatric lupus
Neuropsychiatric lupus affects above 50% of patients with systemic lupus erythematosus and may span from mild symptoms to acute devastating life-threatening ones. Owing to the clinical variability, most pharmacological data rely on small, uncontrolled trials and case reports. The mainstay of therapy...
Saved in:
Published in | Expert review of clinical pharmacology Vol. 9; no. 1; p. 103 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
England
02.01.2016
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Summary: | Neuropsychiatric lupus affects above 50% of patients with systemic lupus erythematosus and may span from mild symptoms to acute devastating life-threatening ones. Owing to the clinical variability, most pharmacological data rely on small, uncontrolled trials and case reports. The mainstay of therapy relies on immune-suppression by glucocorticoids, in adjunction with cyclophosphamide or anti-B-cell therapy, in moderate to severe cases. In selected scenarios (e.g., chorea) intravenous immunoglobulin or plasmapheresis may be effective. Anticoagulation is warranted if anti-phospholipid antibodies are present. In parallel there may be a need for symptomatic treatment such as anti-epileptic or anti-depressive treatments, etc. In the future, more studies addressed to assess pathogenesis and preferred treatments of specific manifestations are needed in order to personalize treatments. |
---|---|
ISSN: | 1751-2441 |
DOI: | 10.1586/17512433.2016.1111137 |